Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70473 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Marco Hoffmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2B6, Breast Neoplasms, Testosterone, Estradiol. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EraPerMed project Artipro by the German Ministery of Research and Education, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Aims
CYP2B6 is a key enzyme involved in the metabolism of steroid hormones such as testosterone and estradiol. Common genetic CYP2B6 variants (*4, *5, *6, *9) are associated with reduced enzymatic activity and have been linked to increased breast cancer risk and poor prognosis. However, the impact of these genetic variants on testosterone and estradiol metabolism in humans is not understood. Therefore, this study aimed to investigate how these pharmacogenetic CYP2B6 variants affect metabolism of these steroid hormones in a human breast cancer model and how this may contribute to altered steroid hormone profiles in breast cancer.
Methods
T47D breast cancer cells were engineered to stably overexpress CYP2B6 wild type and the variants *4, *5, *6 and *9 using a retroviral pMOWS vector system. The metabolites 16α‐/16β‐hydroxytestosterone and 2‐/4‐hydroxyestradiol were analysed using HPLC‐MS/MS after incubation of testosterone or estradiol with CYP2B6 and CYP1B1 supersomes and the modified T47D cells. Conversion of testosterone metabolites to oestrogens by aromatase was also tested.
Results
CYP2B6 supersomes predominantly formed 16β‐hydroxytestosterone and 2‐hydroxyestradiol, while CYP1B1 predominantly produced 16α‐hydroxytestosterone and 4‐hydroxyestradiol. CYP2B6*6 overexpression in T47D increased 16α‐hydroxytestosterone formation, while *4 and 9 showed decreased metabolism compared to wild type. CYP2B6*5 produced reduced 16β‐hydroxytestosterone levels. Aromatase converts 16α‐metabolite to estriol and 16β‐hydroxytestosterone to 16‐epiestriol.
Conclusions
This study demonstrates that common CYP2B6 variants alter testosterone metabolism in a human breast cancer model, potentially disrupting steroid hormone balance and contributing to a tumour‐promoting environment. These findings highlight the potential relevance of pharmacogenetic profiling in breast cancer risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.
- Institute of Molecular Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.
- Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Marco Hoffmann, Julian Peter Müller, Katja Susanne Just
Förderung
- EraPerMed project Artipro by the German Ministery of Research and Education
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Hoffmann, M., Müller, J. P., Düsterhöft, S., Yamoune, S., Just, K. S., & Stingl, J. C. (2026). Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70473
Vancouver
Hoffmann M, Müller JP, Düsterhöft S, Yamoune S, Just KS, Stingl JC. Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70473
BibTeX
@article{Hoffmann2026,
author = {Hoffmann, Marco and Müller, Julian Peter and Düsterhöft, Stefan and Yamoune, Sabrina and Just, Katja Susanne and Stingl, Julia Carolin},
title = {Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70473}
}
EUVIMED